Person:
Díaz-Rubio García, Eduardo

Profile Picture
First Name
Eduardo
Last Name
Díaz-Rubio García
URI
https://hdl.handle.net/20.500.14352/81246
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Medicina
Department
Medicina
Area
Medicina
Identifiers
UCM identifierORCIDScopus Author IDDialnet IDGoogle Scholar ID

Filters

2014 - 20152
Reset filters

Settings

Subject: 616-006.04 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
    (Journal of Experimental & Clinical Cancer Research, 2014) Fernández-Marcelo, Tamara; Frías, Cristina; Pascua, Irene; Juan Chocano, María Del Carmen De; Head, Jacqueline; Gómez, Ana; Hernando Trancho, Florentino; Jarabo Sarceda, José Ramón; Díaz-Rubio García, Eduardo; Torres García, Antonio José; Rouleau, Michèle; Benito De Las Heras, Manuel R.; Iniesta, Pilar; Iniesta Serrano, María Pilar
    Background Considering previous result in Non-Small Cell Lung Cancer (NSCLC), we investigated in human cancer cells the role of PARP3 in the regulation of telomerase activity. Methods We selected A549 (lung adenocarcinoma cell line) and Saos-2 (osteosarcoma cell line), with high and low telomerase activity levels, respectively. The first one was transfected using a plasmid construction containing a PARP3 sequence, whereas the Saos-2 cells were submitted to shRNA transfection to get PARP3 depletion. PARP3 expression on both cell systems was evaluated by real-time quantitative PCR and PARP3 protein levels, by Western-blot. Telomerase activity was determined by TRAP assay. Results In A549 cells, after PARP3 transient transfection, data obtained indicated that twenty-four hours after transfection, up to 100-fold increased gene expression levels were found in the transfected cells with pcDNA/GW-53/PARP3 in comparison to transfected cells with the empty vector. Moreover, 48 hours post-transfection, telomerase activity decreased around 33%, and around 27%, 96 hours post-transfection. Telomerase activity average ratio was 0.67 ± 0.05, and 0.73 ± 0.06, respectively, with significant differences. In Saos-2 cells, after shRNA-mediated PARP3 silencing, a 2.3-fold increase in telomerase activity was detected in relation to the control. Conclusion Our data indicated that, at least in some cancer cells, repression of PARP3 could be responsible for an increased telomerase activity, this fact contributing to telomere maintenance and, therefore, avoiding genome instability.
  • Thumbnail Image
    Item
    BRCA2 gene mutations and coagulation-associated biomarkers
    (Thrombosis and Haemostasis, 2015) Pérez Segura, Pedro; Zamorano León, José Javier; Acosta, Daniel; Santos Sancho, Juana María; Modrego, Javier; Caldés, Trinidad; de la Hoya, Miguel; Díaz-Rubio García, Eduardo; Díaz Millán, Isabel; Heras Jiménez, Natalia De Las; Rico Zalba, Luis; Lahera Julia, Vicente; Melander, Olle; López Farre, Antonio José
    Thromboembolic events are the second cause of death in cancer patients, although the mechanisms underlying this increased thromboembolic risk remain unclear. The aims of this study were to examine whether BRCA2 gene mutations may modify the circulating levels of thrombocoagulation biomarkers and whether breast cancer development may influence changes in such circulating biomarkers. The study was performed in 25 women with mutations in the BRCA2 gene (n=12 breast cancer, n=13 breast cancer-free) and in 13 BRCA2 non-mutant controls. Results revealed that plasma levels of fibrinogen gamma chain isotypes 2 and 3, haptoglobin isotypes 4 and 5, serotransferrin isotypes 3 and 4 and convertase C3/C5 isotypes 4 and 5 were significantly higher in BRCA2 mutation carriers compared to controls. However, plasma levels of vitamin D binding protein isotype 1 and alpha1-antitrypsin isotypes 2, 3 and 4 were significantly decreased in BRCA2 mutation carriers compared to controls. Plasma expression of PF4 and P-selectin was significantly higher in BRCA2 mutations carriers than in controls. BRCA2 truncated mutations conserving a binding region for RAD51 were associated with increased plasma levels of alpha1-antitrypsin isotypes 3 and 4 with respect to women showing BRCA2 mutations that loss the binding RD51 region to BRCA2. Only plasma levels of vitamin D binding protein isotypes 1 and 3 were significantly reduced and alpha 1-antitrypsin isotype 1 was increased in cancer-free BRCA2 mutation carriers compared to BRCA2 mutation carriers with breast cancer. The presence of BRCA2 mutations is associated with increased plasma levels of thrombo-coagulating-related proteins, which are independent to breast cancer development.